Find a Clinical Trial
Filter
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
Relapsed or refractory myeloma
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
M23-362
Diffuse large B-cell lymphoma, Follicular lymphoma, Lymphomas (adult)
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
HGB-210
Sickle cell anemia
All genders
2-50
Recruiting now
Department of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Cancer Center
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Diffuse large B-cell lymphoma
All genders
75+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)
Bladder cancer
All genders
18+
Recruiting now
Department of Medicine, Cancer Center
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Lymphomas (adult)
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
ANHL1931
Lymphoma
All genders
2+
Recruiting now
Department of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Cancer Center
A Study of the Pharmacokinetics, Safety, and Efficacy of ASTX727
Acute myeloid leukemia (AML)
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
CAR-T detection by IVFC
Lymphoma
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Feasibility of a new method for non-invasive monitoring of low-grade bladder cancer
Bladder cancer
All genders
18-90
Recruiting now
Department of Urology